Related Experiment Video
Updated: Apr 25, 2026

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
Published on: February 10, 2023
Clinical decision rules and D-Dimer in venous thromboembolism: current controversies and future research priorities
Marc A Rodger1, Gregoire Le Gal2, Philip Wells2
1Hematology, University of Ottawa and The Ottawa Hospital, Ottawa, ON Canada; Medicine, University of Ottawa and The Ottawa Hospital, Ottawa, ON Canada; Obstetrics and Gynaecology, University of Ottawa and The Ottawa Hospital, Ottawa, ON Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON Canada.
Abstract:
Venous thromboembolism (VTE) is a potentially lethal clinical condition that is suspected in patients with common clinical complaints, in many and varied, clinical care settings. Once VTE is diagnosed, optimal therapeutic management (thrombolysis, IVC filters, type and duration of anticoagulants) and ideal therapeutic management settings (outpatient, critical care) are also controversial. Clinical prediction tools, including clinical decision rules and D-Dimer, have been developed, and some validated, to assist clinical decision making along the diagnostic and therapeutic management paths for VTE. Despite these developments, practice variation is high and there remain many controversies in the use of the clinical prediction tools. In this narrative review, we highlight challenges and controversies in VTE diagnostic and therapeutic management with a focus on clinical decision rules and D-Dimer.
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism III: Nursing Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

